JMP Securities
http://www.jmpsecurities.com/index.htmlJMP Securities provides investment banking services, institutional brokerage, and equity research to public and private growth companies. Equity research is the backbone of the firm and the industries the firm covers are: Business Services, Financial Services, Real Estate, Consumer, Healthcare, and Technology. The firm is headquartered in San Francisco, CA and is a subsidiary of JMP Group (NYSE: JMP).
-
Sarepta Therapeutics (SRPT) PT Raised to $95 at JMP Securities
-
Sarepta Therapeutics (SRPT) PT Lowered to $48 at JMP Securities
-
Sarepta Therapeutics (SRPT) PT Lowered to $65 at JMP Securities Following Update, Survey; Sees Upside to ~$160
-
Notable 52-Week Highs and Lows 9/28: (SRPT) (NVDA) (CLD) High; (FGP) (GBSN) Low
-
Pre-Open Stock Movers 09/28: (SEED) (AVXL) (ATHX) Higher; (GALT) (TPX) (SONC) Lower (more...)
-
Sarepta Therapeutic's (SRPT) Price Target Raised to $90 at JMP Securities
-
JMP Securities Upgrades Sarepta Therapeutic (SRPT) to Market Outperform
-
Notable Analyst Rating Changes 5/3: (MEP) (RSG) (AXTI) Upgraded; (CYH) (UTX) (SRPT) Downgraded
-
JMP Securities Downgrades Sarepta Therapeutic (SRPT) to Market Underperform
-
JMP Securities Downgrades Sarepta Therapeutic (SRPT) to Market Perform
-
Notable Analyst Rating Changes 9/24: (SNX) (MRVL) (FCN) Upgraded; (UL) (MS) (ASNA) Downgraded
-
Pre-Open Stock Movers 9/24: (LPCN) (MACK) (ACOR) Higher; (ECTE) (ATOS) (GTI) Lower (more...)
-
Unusual 11 Mid-Day Movers 04/21: (SRPT) (CBEY) (ASTM) Higher; (MGI) (XXII) (WLT) Lower
-
JMP Securities Upgrades Sarepta Therapeutic (SRPT) to Market Outperform
-
JMP Securities Downgrades Sarepta Therapeutic (SRPT) to Market Perform
-
Sarepta Therapeutic's (SRPT) Eteplirsen Could Have Safety Advantage
-
Sarepta Therapeutics (SRPT) 4.95M Share Offering Priced at $25.25
-
Sarepta (SRPT) Trades Higher on Eteplirsen Phase II Update, Analyst Comments
-
Notable Analyst Rating Changes 08/27: (WY) (MPC) (KEG) Upgraded; (LYB) (PEG) (ADSK) Downgraded

